apollo
0
Prescription drug
 Trailing icon
Consult Doctor

Composition

MIDOSTAURIN-25MG

Manufacturer/Marketer

Intas Pharmaceuticals Ltd

Consume Type

ORAL

Return Policy

Not Returnable

Expires on or after

Jan-25

for this medicine

About Inflitza 25 Softgel Capsule

Inflitza 25 Softgel Capsule belongs to the group of medicines called protein kinase inhibitors used to treat acute myeloid leukaemia (AML). It is sometimes, also used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL).

Inflitza 25 Softgel Capsule contains Midostaurin, which works by blocking the action of kinase enzymes in abnormal cells and stops their division and growth. Thereby, it helps prevent the spread of cancer and mast cells.

Inflitza 25 Softgel Capsule may cause certain side effects such as nausea, vomiting, headache, fever, musculoskeletal pain, and upper abdominal pain. Most of these side effects may not require medical attention and resolve gradually over time. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen. Take Inflitza 25 Softgel Capsule as prescribed by your doctor.

Discontinue taking Inflitza 25 Softgel Capsule and inform your physician if you observe any allergic reactions. Inform the doctor about your health condition and medications to rule out any side effects. Do not take Inflitza 25 Softgel Capsule if you are pregnant or breastfeeding. This medicine is not recommended for children as safety and effectiveness have not been established.

Uses of Inflitza 25 Softgel Capsule

Treatment of Acute myeloid leukaemia (AML), aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL)

Medicinal Benefits

Inflitza 25 Softgel Capsule belongs to the group of medicines called protein kinase inhibitors used to treat acute myeloid leukaemia (AML) in patients who are FLT3 mutation-positive. It is also used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL). Inflitza 25 Softgel Capsule contains Midostaurin, which works by blocking the action of kinase enzymes in abnormal cells and stops their division and growth. Thereby, it helps prevent the spread of cancer and mast cells.

Side Effects of Inflitza 25 Softgel Capsule

  • Nausea
  • Vomiting
  • Headache
  • Dizziness, light-headedness
  • Upper abdominal pain
  • Fever
  • Joint pain
  • Back pain
  • Throat pain
  • Mouth sores
  • Nose bleeds

Directions for Use

Take Inflitza 25 Softgel Capsule with food. Swallow the medicine as a whole with water; do not crush or chew it. Take this medicine exactly as advised by the doctor.

Storage

Store in a cool and dry place away from sunlight

Drug Warnings

Do not take Inflitza 25 Softgel Capsule if you are allergic to any of its components, if you are taking medicines used to treat tuberculosis (rifampicin), epilepsy (carbamazepine or phenytoin), prostate cancer (enzalutamide), or herbal products (St. John’s Wort) or if you are pregnant or breastfeeding. Inform the doctor if you have any infections, heart disorders, lung, kidney or liver diseases. Seek immediate medical attention if you experience symptoms of low white blood cell count (fever, sore throat, mouth ulcers), lung problems (fever, chest pain, cough with or without mucous, trouble breathing or shortness of breath), or heart problems (chest pain or discomfort, fainting, dizziness, light-headedness, shortness of breath, blue discolouration of your lips, hands or feet, or swelling of your lower limbs).

Therapeutic Class

KINASE INHIBITORS

Drug Interactions

Drug-Drug Interactions: Inform the doctor if you are taking medicines used to treat tuberculosis (rifampicin), epilepsy (carbamazepine or phenytoin), prostate cancer (enzalutamide), infections (ketoconazole, clarithromycin), HIV (ritonavir, efavirenz), depression (nefazodone, bupropion), control levels of fat in your blood (atorvastatin, rosuvastatin), muscle relaxant (tizanidine, chlorzoxazone), or herbal product used to treat depression (St. John’s Wort).

Drug-Food Interactions: Do not consume grapefruit and its juice during treatment with Inflitza 25 Softgel Capsule as it may significantly increase the blood levels of the medicine.

Drug-Disease Interactions: Inform the doctor if you have breathing or lung problems, irregular heartbeat, QT prolongation, infections, or liver or kidney disease.

Drug-Drug Interactions Checker List

  • RIFAMPICIN
  • CARBAMAZEPINE
  • PHENYTOIN
  • ENZALUTAMIDE
  • KETOCONAZOLE
  • CLARITHROMYCIN
  • RITONAVIR
  • EFAVIRENZ
  • NEFAZODONE
  • BUPROPION
  • ATORVASTATIN
  • ROSUVASTATIN
  • TIZANIDINE
  • CHLORZOXAZONE
  • ST JOHN'S WORT

Diet & Lifestyle Advise

  • Eat a healthy diet and exercise regularly to maintain proper weight.
  • Avoid smoking and alcohol consumption.
  • Include vegetables and fruits in your diet.
  • Avoid fast food, fried food, processed meats, refined carbs and added sugar.
  • Get optimal sleep; rest well.
  • Drink enough water to stay hydrated.

Habit Forming

No

What if I have taken an overdose of Inflitza 25 Softgel Capsule

Please do not exceed the recommended dose, as it might cause an overdose. Signs and symptoms of an overdose of Inflitza 25 Softgel Capsule may include feeling cold, goosebumps, increased blood pressure (headache, flushing, blurred vision, pounding heartbeat) and trouble urinating. Seek immediate medical attention if you observe these symptoms or think you might have taken too much. Do this even if there are no signs of discomfort or poisoning.

Special Advise

  • If you are able to become pregnant, your doctor will perform a pregnancy test within 7 days before you start the treatment. 
  • Women of reproductive potential and males with partners who are able to become pregnant must use reliable and effective birth control pills during treatment and for four months after receiving the last dose.
  • Your doctor will advise regular blood tests during the treatment to monitor blood cell count, electrolytes, heart and lung functioning.

Disease/Condition Glossary

Acute myeloid leukaemia: Acute myeloid leukaemia, also called acute myelogenous leukaemia or acute nonlymphocytic leukaemia, is the cancer of blood and bone marrow with excess immature white blood cells. Symptoms include fever, recurrent infections, fatigue, and easy bruising.

Aggressive systemic mastocytosis (ASM): It is a clonal mast cell disease characterised by the progressive growth of neoplastic cells in organs, leading to organopathy. Signs and symptoms include fatigue, nausea, abdominal pain, diarrhoea, bloating, skin redness, warmth, headache, low blood pressure, shortness of breath, and light-headedness.

Systemic mastocytosis with associated haematological neoplasm (SM-AHN): It is characterised by the abnormal accumulation of neoplastic mast cells in one or more organs, mainly the bone marrow, associated with another hematologic neoplasm of non-mast cell nature.

Mast cell leukaemia (MCL): It is characterised by abnormal growth and build-up of mast cells (a type of white blood cell produced by the bone marrow). Symptoms include low blood pressure, itchy skin, and rashes.

bannner image

Alcohol

Consult your doctor

It is not known if alcohol affects Inflitza 25 Softgel Capsule. Please consult your doctor.

bannner image

Pregnancy

Unsafe

Inflitza 25 Softgel Capsule is not recommended during pregnancy as it may harm your unborn baby. Therefore, if you are pregnant or planning for pregnancy, talk to the doctor for advice.

bannner image

Breast Feeding

Unsafe

Inflitza 25 Softgel Capsule may harm the baby. Avoid breastfeeding during treatment with Inflitza 25 Softgel Capsule and for at least 4 months after stopping the treatment.

bannner image

Driving

Caution

Inflitza 25 Softgel Capsule may cause dizziness and vertigo. Be cautious while driving or operating machinery.

bannner image

Liver

Consult your doctor

If you have a pre-existing or a history of liver disease, inform your doctor before receiving Inflitza 25 Softgel Capsule. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.

bannner image

Kidney

Consult your doctor

If you have a pre-existing or a history of kidney disease, inform your doctor before receiving Inflitza 25 Softgel Capsule. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.

bannner image

Children

Caution

The safety and effectiveness of Inflitza 25 Softgel Capsule in children below 18 years have not been established.

Country of origin

India

Manufacturer/Marketer address

Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.
Other Info - INF0386

FAQs

Inflitza 25 Softgel Capsule is used to treat Acute myeloid leukaemia (AML), aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL).
Inflitza 25 Softgel Capsule works by blocking the action of kinase enzymes in abnormal cells and stops their division and growth. Thereby, it helps prevent the spread of cancer and mast cells.
If you miss a dose of Inflitza 25 Softgel Capsule, take your next dose at the scheduled time. Avoid taking an extra dose to make up for the missed dose.
Inflitza 25 Softgel Capsule may reduce fertility in men and women. Before starting the treatment, discuss with the doctor if you have any concerns regarding fertility.
Continue taking Inflitza 25 Softgel Capsule even if you feel well. Do not stop taking Inflitza 25 Softgel Capsule without talking to the doctor.
If you vomit after taking Inflitza 25 Softgel Capsule, do take another dose. Continue with your regular dosing schedule and take the next dose at your scheduled time. If nausea or vomiting persists or worsens, consult the doctor.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.

Add to Cart